Tirzepatide in the GP QOF 2026/27: What the Mounjaro Obesity Change Means in Primary Care

From 1 April 2026, NHS England incorporated tirzepatide (Mounjaro) prescribing for obesity into the 2026/27 GP contract through new QOF indicators. NICE TA1026 recommends it for adults with a BMI of at least 35 kg/m² (2.5 kg/m² lower for several ethnic groups), alongside a reduced-calorie diet and increased physical activity. GPs are not mandated to prescribe it, and what you can actually prescribe depends on local commissioning. Here is the operational summary.

This post is a plain-English summary for busy clinicians. We summarise; we do not replace NICE or NHS England guidance, and nothing here substitutes for clinical judgement on individual patients.

What changed on 1 April 2026

The 2026/27 GP contract brought tirzepatide obesity prescribing into the QOF. The updated indicators explicitly recognise GLP-1 receptor agonists and dual GIP/GLP-1 agonists — tirzepatide is the latter — in the management of both type 2 diabetes and obesity.

For most UK GPs, this is the change they will meet in their next QOF cycle. It is the reason "do we prescribe Mounjaro for obesity now?" has become a routine question in primary care rather than a specialist-service one.

Who is eligible: the Mounjaro criteria under TA1026

NICE TA1026 recommends tirzepatide for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity, for adults with:

• an initial BMI of at least 35 kg/m², with
• the threshold lowered by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.

The diet-and-activity wrap-around is part of the recommendation, not an optional extra — tirzepatide is recommended as one component of a weight-management approach, not a standalone prescription. The exact criteria, including any weight-related comorbidity requirements, are set out in TA1026; check it before assuming eligibility.

What "prescribing moves to general practice" actually means

This is the part that varies most, and it is worth being precise about.

GP practices are not mandated to prescribe tirzepatide for obesity. In some areas, local weight-management services that previously held this prescribing are transferring responsibility to general practice. In others, the pathway is still being established. And where tirzepatide is not locally commissioned, practices cannot prescribe it at all.

The practical consequence: the answer to "can I prescribe Mounjaro for obesity?" is a local one. Your ICB or Health Board position, and your local formulary, determine what is possible — the QOF change sets the national direction, not the local permission.

How it sits alongside the diabetes GLP-1 picture

Tirzepatide's obesity indication arrives on top of an already-busy GLP-1 landscape in primary care. The same drug class sits at the centre of the 2026 diabetes changes: NICE updated NG28 in February 2026, and SGLT2 inhibitors moved to first-line for most adults with type 2 diabetes. If you are getting to grips with the prescribing shifts together, our companion summaries are NICE NG28 February 2026: SGLT2 inhibitors first-line and SGLT2 inhibitors in UK primary care 2026.

Semaglutide (Wegovy) for obesity has largely been delivered through specialist weight-management services rather than routine general practice — another reason the tirzepatide-into-QOF move is the one changing the GP workload directly.

What this means for UK practice

The headline for primary care: tirzepatide for obesity is now a QOF-recognised part of the GP contract, with NICE TA1026 setting eligibility and local commissioning setting permission. The highest-yield first step is to check your local position — ICB/Health Board commissioning and formulary status — before building it into routine reviews, because that is what determines whether you can prescribe at all.

For eligible patients where it is commissioned, remember the wrap-around: diet, physical activity, and the monitoring and titration set out in the BNF are part of the package, not optional.

A note on what this post is — and is not

This is a guideline and policy summary for awareness. It is not a substitute for NICE TA1026, the NHS England interim commissioning guidance, the BNF, or local prescribing policy. Clinical and prescribing decisions remain the responsibility of the prescribing clinician.

The Monday Clinical Brief publishes weekly summaries of the most important new papers and guideline updates across 31 UK medical specialties — including prescribing and policy changes like this one. We surface them, summarise them, and link to them, so practice-changing material does not get missed in a busy week. For the bigger picture, see our pillar guide on how to keep up with the medical literature.

Subscribe to The Monday Clinical Brief — £20 a year, no advertising, no sponsored content, just every week's most important reading delivered to your inbox on Monday morning.